Spots Global Cancer Trial Database for vaccine therapy
Every month we try and update this database with for vaccine therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. | NCT04963413 | Glioblastoma | Autologous DCs ... | 18 Years - 90 Years | University of Florida | |
| Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer | NCT00614601 | Pancreatic Canc... | HyperAcute(R)-P... | 18 Years - | Lumos Pharma | |
| Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 | NCT03721679 | Solid Cancer | Poly-ICLC combi... | 18 Years - | Oncovir, Inc. | |
| Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma | NCT00001703 | Renal Cell Carc... | incomplete Freu... von Hippel-Lind... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | NCT01774578 | Non-small Cell ... Progression of ... Non-small Cell ... | Docetaxel HyperAcute®-Lun... Gemcitabine Pemetrexed | 18 Years - | Lumos Pharma | |
| p53 Vaccine for Ovarian Cancer | NCT00001827 | Ovarian Neoplas... | aldesleukin incomplete Freu... p53 peptide vac... sargramostim therapeutic aut... in vitro-treate... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer | NCT06324240 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Early Stage Tri... Locally Advance... Metastatic Trip... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Recurrent Breas... Unresectable Tr... | Ipilimumab Pembrolizumab Vaccine Therapy | 18 Years - | Emory University | |
| RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. | NCT04963413 | Glioblastoma | Autologous DCs ... | 18 Years - 90 Years | University of Florida | |
| Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma | NCT00001703 | Renal Cell Carc... | incomplete Freu... von Hippel-Lind... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma | NCT03631043 | Smoldering Plas... | Biopsy Specimen... Lenalidomide Vaccine Therapy | 18 Years - | M.D. Anderson Cancer Center | |
| Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome | NCT00270452 | Myelodysplastic... | WT1 and PR1 Pep... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) | NCT02179515 | Lung Cancer Breast Cancer Prostate Cancer Tumors (Others) Ovarian Cancer | MVA-brachyury- ... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer | NCT01433172 | Lung Cancer Adenocarcinoma | Phase I - GM.CD... Phase II - GM.C... Phase II - GM.C... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer | NCT02405585 | Pancreatic Canc... Pancreatic Carc... | mFOLFIRINOX Algenpantucel-L... SBRT Gemcitabine | 18 Years - | Lumos Pharma | |
| A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas | NCT01130077 | Newly Diagnosed... Newly Diagnosed... Recurrent Pedia... Recurrent Pedia... | HLA-A2 restrict... Poly-ICLC | 12 Months - 21 Years | University of Pittsburgh | |
| Cancer Vaccine Targeting Brachyury Protein in Tumors | NCT01519817 | Neoplasms Malignant Solid... Colon Neoplasms Adenocarcinoma | GI-6301 (Yeast ... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma | NCT03631043 | Smoldering Plas... | Biopsy Specimen... Lenalidomide Vaccine Therapy | 18 Years - | M.D. Anderson Cancer Center | |
| Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer | NCT00614601 | Pancreatic Canc... | HyperAcute(R)-P... | 18 Years - | Lumos Pharma | |
| Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer | NCT01836432 | Pancreatic Canc... Pancreatic Carc... Locally Advance... | FOLFIRINOX Algenpantucel-L... 5-FU Chemoradia... Gemcitabine Capecitabine Nab-Paclitaxel | 18 Years - | Lumos Pharma | |
| Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) | NCT03396575 | Diffuse Intrins... Brain Stem Glio... | TTRNA-DC vaccin... TTRNA-xALT Cyclophosphamid... Dose-Intensifie... Td vaccine Autologous Hema... | 3 Years - 30 Years | University of Florida | |
| Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer | NCT00614601 | Pancreatic Canc... | HyperAcute(R)-P... | 18 Years - | Lumos Pharma | |
| Immunotherapy Study for Surgically Resected Pancreatic Cancer | NCT01072981 | Pancreatic Canc... | HyperAcute-Panc... Gemcitabine 5FU Chemoradiat... | 18 Years - | Lumos Pharma | |
| Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | NCT02460367 | Non-small Cell ... Progression of ... Non-small Cell ... | Docetaxel Tergenpumatucel... Indoximod | 18 Years - | Lumos Pharma | |
| Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | NCT01376505 | Malignant Solid... Breast Cancer Malignant Tumor... GIST Ovarian Cancer | HER-2 vaccine Extension HER-2... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | NCT02460367 | Non-small Cell ... Progression of ... Non-small Cell ... | Docetaxel Tergenpumatucel... Indoximod | 18 Years - | Lumos Pharma | |
| Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas | NCT03334305 | Malignant Gliom... High Grade Glio... | TTRNA-DC vaccin... Dose-intensifie... Autologous Hema... TTRNA-xALT Td vaccine | 3 Years - 21 Years | University of Florida | |
| Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer | NCT06324240 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Early Stage Tri... Locally Advance... Metastatic Trip... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Recurrent Breas... Unresectable Tr... | Ipilimumab Pembrolizumab Vaccine Therapy | 18 Years - | Emory University | |
| Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | NCT02460367 | Non-small Cell ... Progression of ... Non-small Cell ... | Docetaxel Tergenpumatucel... Indoximod | 18 Years - | Lumos Pharma | |
| Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) | NCT02179515 | Lung Cancer Breast Cancer Prostate Cancer Tumors (Others) Ovarian Cancer | MVA-brachyury- ... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer | NCT02362451 | Prostatic Neopl... Prostate Cancer | Autologus elutr... Multi-epitope (... | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
